Serum Free Fatty Acid Metabolite Biomarkers of Lung Cancer
This study aims to evaluate the performance of serum free fatty acids as biomarkers for the identification of lung cancer.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jun 20, 2017 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- The Cleveland Clinic
- Interventions being studied
- Other: serum sample
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Age from 40 to 80
- Lung adenocarcinoma with pathological diagnosis
- Lung squamous cell carcinoma with pathological diagnosis
- Control patients should have at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
\- Lung cancer patient without serum sample before the initiation of treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cleveland ClinicCleveland, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 20, 2017. Always confirm current availability with the study team.